The Drug Utilisation Sub-Committee (DUSC) of the Pharmaceutical Benefits Advisory Committee (PBAC) held its 113th meeting on 6 - 7 February 2025.

DUSC has a national focus of excellence in collecting, analysing and interpreting data on the utilisation of medicines in Australia for use by the PBAC. Review of the utilisation of medicines is an essential management tool in facilitating the objectives of the National Medicines Policy.

The PBAC is also committed to understanding consumer perspectives and integrating them into consideration of medicines and vaccines. Consumers are able to provide their views about medicine utilisation reviews to the PBAC [via the Office of Health Technology Assessment (OHTA) consultation hub.](https://ohta-consultations.health.gov.au/)

## Submissions to the PBAC

DUSC considered 14 category 1 submissions which had been received for the March 2025 meeting of PBAC. DUSC provided detailed advice to the PBAC on projected usage and financial cost for the submissions where there was high cost, uncertain utilisation, first medicine in class or quality use of medicines concerns. The agenda for the March 2025 PBAC meeting can be found on the [PBS website](https://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/agenda/march-2025-pbac-meeting).

## Upcoming Utilisation Analysis of PBS Listed Medicines

An additional meeting of DUSC was scheduled for 4 April 2025 to consider the utilisation of the following medicines which were recommended at the 3-4 October 2024 DUSC meeting:

* Fluticasone furoate+umeclidinium+vilanterol for severe asthma.
* Imatinib, ripretinib and sunitinib for gastrointestinal stromal tumour.
* Zanubrutinib for Waldenstrom macroglobulinaemia.

**Analysis of single or multiple medicines in a treatment area**

* Atezolizumab for hepatocellular carcinoma​.
* Cemiplimab for cutaneous squamous cell carcinoma. ​
* Nivolumab for gastro-oesophageal cancers.​
* Nusinersen for spinal muscular atrophy in adults​.

An outcome statement will be available following each meeting of DUSC. For further information, please contact the DUSC Secretariat at [DUSC@health.gov.au](mailto:DUSC@health.gov.au).

Professor Chris Etherton-Beer

Chair

Drug Utilisation Sub-Committee